Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Highmark inks outcomes contract with second pharma brand

Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

Read More »

Novo Nordisk Q2 2018 sales disappoint

Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.

Read More »

Sanofi Q2 Report: Sales Down, But Company Has Plans To Fix Diabetes Division

Paris-based Sanofi reported a decrease in second-quarter 2018 net sales of 5.7 percent, down to 8.176 billion euros.

Read More »

Recent Study Suggests Diabetes Treatment May Have Potential in Parkinson’s Disease

Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.

Read More »

Eli Lilly to take animal health unit public, profit beats estimates

Eli Lilly and Co. will take the company’s Elanco animal health business public and posted better-than-expected quarterly profit, helped by demand for the diabetes drugs Trulicity and Humalog.

Read More »

Janssen Halts Phase III Kidney Disease Trial Early After Endpoints Were Met

Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.

Read More »

Johnson & Johnson profit beat fueled by strength in pharma business

J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

Sanofi beefing up diabetes pipeline, sees growth returning

Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.

Read More »

High blood pressure in pregnancy tied to heart disease risk afterward

Women who develop high blood pressure during pregnancy may be more likely to experience it again later or be diagnosed with other risk factors for heart disease like high cholesterol or diabetes, a U.S. study suggests.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom